Overall, this data suggests that arming the virus with IL-12 and including a further therapeutic boost with either α-PD1 or a VV expressing soluble PD1 (VV-msPD1) creates a highly effective therapeutic regime for long-term elimination of lung cancer in murine models. This evidence concerns the gene PDCD1 and lung carcinoma.